Adults with dermatomyositis may experience weight loss or a low-grade fever, have inflamed lungs, and be sensitive to light. Children and adults with dermatomyositis may develop calcium deposits, which appear as hard bumps under the skin or in the muscle (called calcinosis). Calcinosis most often occurs 1-3 years after the disease begins. These deposits are seen more often in children with dermatomyositis than in adults. In some cases of dermatomyositis, distal muscles (muscles located away from the trunk of the body, such as those in the forearms and around the ankles and wrists) may be affected as the disease progresses. Dermatomyositis may be associated with collagen-vascular or
The Human Phenotype Ontology (HPO) provides the following list of features that have been reported in people with this condition. Much of the information in the HPO comes from Orphanet, a European rare disease database. If available, the list includes a rough estimate of how common a feature is (its frequency). Frequencies are based on a specific study and may not be representative of all studies. You can use the MedlinePlus Medical Dictionary for definitions of the terms below.
| Signs and Symptoms | Approximate number of patients (when available) |
| Abnormality of the eyelid | Very frequent (present in 80%-99% of cases) |
| Autoimmunity | Very frequent (present in 80%-99% of cases) |
| EMG abnormality | Very frequent (present in 80%-99% of cases) |
| Erythema | Very frequent (present in 80%-99% of cases) |
| Inflammatory myopathy | Very frequent (present in 80%-99% of cases) |
| Myalgia | Very frequent (present in 80%-99% of cases) |
| Periorbital edema | Very frequent (present in 80%-99% of cases) |
| Proximal muscle weakness | Very frequent (present in 80%-99% of cases) |
| Abnormal hair quantity | Frequent (present in 30%-79% of cases) |
| Abnormality of the nail | Frequent (present in 30%-79% of cases) |
| Acrocyanosis | Frequent (present in 30%-79% of cases) |
| Arthralgia | Frequent (present in 30%-79% of cases) |
| Frequent (present in 30%-79% of cases) |
|
| Chondrocalcinosis | Frequent (present in 30%-79% of cases) |
| Diffuse reticular or finely nodular infiltrations | Frequent (present in 30%-79% of cases) |
| Dry skin | Frequent (present in 30%-79% of cases) |
| Fatigue | Frequent (present in 30%-79% of cases) |
| Interstitial pulmonary abnormality | Frequent (present in 30%-79% of cases) |
| Muscular |
Frequent (present in 30%-79% of cases) |
| Papule | Frequent (present in 30%-79% of cases) |
| Pruritus | Frequent (present in 30%-79% of cases) |
| Pulmonary fibrosis | Frequent (present in 30%-79% of cases) |
| Recurrent respiratory infections | Frequent (present in 30%-79% of cases) |
| Respiratory insufficiency | Frequent (present in 30%-79% of cases) |
| Skin ulcer | Frequent (present in 30%-79% of cases) |
| Weight loss | Frequent (present in 30%-79% of cases) |
| Abnormality of eosinophils | Occasional (present in 5%-29% of cases) |
| Aplasia/Hypoplasia of the skin | Occasional (present in 5%-29% of cases) |
| Breast carcinoma | Occasional (present in 5%-29% of cases) |
| Cellulitis | Occasional (present in 5%-29% of cases) |
| Cutaneous photosensitivity | Occasional (present in 5%-29% of cases) |
| Dysphonia | Occasional (present in 5%-29% of cases) |
| Feeding difficulties in infancy | Occasional (present in 5%-29% of cases) |
| Fever | Occasional (present in 5%-29% of cases) |
| Gangrene | Occasional (present in 5%-29% of cases) |
| Gastrointestinal stroma |
Occasional (present in 5%-29% of cases) |
| Lung adenocarcinoma | Occasional (present in 5%-29% of cases) |
| Lymphoma | Occasional (present in 5%-29% of cases) |
| Myocardial infarction | Occasional (present in 5%-29% of cases) |
| Myocarditis | Occasional (present in 5%-29% of cases) |
| Pericarditis | Occasional (present in 5%-29% of cases) |
| Pulmonary arterial |
Occasional (present in 5%-29% of cases) |
| Sinus tachycardia | Occasional (present in 5%-29% of cases) |
| Telangiectasia of the skin | Occasional (present in 5%-29% of cases) |
| Vasculitis | Occasional (present in 5%-29% of cases) |
Research helps us better understand diseases and can lead to advances in diagnosis and treatment. This section provides resources to help you learn about medical research and ways to get involved.
Support and advocacy groups can help you connect with other patients and families, and they can provide valuable services. Many develop patient-centered information and are the driving force behind research for better treatments and possible cures. They can direct you to research, resources, and services. Many organizations also have experts who serve as medical advisors or provide lists of doctors/clinics. Visit the group’s website or contact them to learn about the services they offer. Inclusion on this list is not an endorsement by GARD.
Living with a genetic or rare disease can impact the daily lives of patients and families. These resources can help families navigate various aspects of living with a rare disease.
These resources provide more information about this condition or associated symptoms. The in-depth resources contain medical and scientific language that may be hard to understand. You may want to review these resources with a medical professional.
Don’t Miss the NCATS Toolkit for Patient-Focused Therapy Development Event
August 31, 2017
Funding Opportunities Now Available for the Undiagnosed Diseases Network (UDN) Phase II
August 30, 2017
IRDiRC Goals 2017-2027: New Rare Disease Research Goals for the Next Decade
August 10, 2017
International Consensus Conference to Develop Improvement Criteria for Juvenile Dermatomyositis and Adult Dermatomyositis and Polymyositis: Workshop to Define Minimal Clinical Improvement and Major Clinical Response
Monday, June 9, 2014 -
Tuesday, June 10, 2014
Location: Hotel Novotel La Defense,
Paris,
France
Description: Anticipated goals and use of results: We anticipate developing composite endpoints for future clinical trials that will be fully validated, endorsed by the ACR and EULAR, and used by all forthcoming myositis clinical trials and clinical studies as clinical endpoints. A likely secondary outcome of this work would be the stimulus to develop new therapies for myositis and conduct clinical trials of new therapeutic agents in myositis patients, given adequate ways to assess efficacy of new therapies in trials.
Contact: Dr. Sheila Newton(919) 541-4343
Co-funding Institute(s): National Institute of Environmental Health Sciences, Office of Rare Diseases Research
- 135KB)
- 340KB)
Workshop on Inflammatory Myopathy Wednesday, April 5, 2000 -
Thursday, April 6, 2000
Location: NIH Campus,
Bethesda,
MD
Description: The goal of this workshop was to provide a forum for researchers in the areas of myositis, muscle biology, and immunology to review the current status of research on inflammatory myopathies and explore potential new avenues of research.
Contact: Dr. Paul Plotz(301) 496-1474
Co-funding Institute(s): National Institute of Arthritis and Musculoskeletal and Skin Diseases
The following diseases are related to Dermatomyositis. If you have a question about any of these diseases, you can contact GARD.
Questions sent to GARD may be posted here if the information could be helpful to others. We remove all identifying information when posting a question to protect your privacy. If you do not want your question posted, please let us know. Submit a new question
My father was diagnosed with dermatomyositis and has some long-lasting symptoms. Is it possible that radiation exposure could be contributing to his condition? See answer
My mother has been diagnosed with dermatomyositis. She has not responded to the treatments she has received. Can you provide information about the symptoms, treatment, and prognosis for this condition? See answer
